Syncona founds new gene therapy company

By Sam Kerr
19 Nov 2020

Syncona, the UK life sciences investor, has launched a new gene therapy company, through a £45m series A private fundraising round. The company could be a future candidate for a lucrative biotech listing.

The new firm, Purespring, will be one of the first adeno-associated virus (AAV) gene therapy companies focused on the kidneys.

AAV gene therapy is a method through which an adeno-associated virus is transformed from a naturally occurring virus into a delivery mechanism for gene treatment.

Series A financing ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial